NCT07498075 Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers
| NCT ID | NCT07498075 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | HPV |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,340 participants |
| Start Date | 2026-05-07 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,340 participants in total. It began in 2026-05-07 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates whether different types of digital health communication can increase parents' intention to vaccinate their daughters against human papillomavirus (HPV) in Nigeria. HPV vaccination is recommended for girls aged 9-14 years and helps prevent cervical cancer, yet vaccination rates remain low. Parents of eligible, unvaccinated girls will be randomly assigned to receive one of several types of digital content delivered online. These include: (1) a short chatbot conversation based on motivational interviewing principles, (2) an interactive game designed to help parents recognize and resist common forms of vaccine misinformation, (3) a set of short edutainment videos about HPV vaccination, (4) standard informational infographics about HPV vaccination from a national public health agency, or (5) unrelated health content about menstruation. The main outcome is parents' self-reported intention to vaccinate their daughter against HPV, measured immediately and one week after exposure to the assigned content. Additional outcomes include HPV-related knowledge, perceptions of vaccine safety, willingness to recommend the vaccine to others, and self-reported vaccine uptake at 1-week and 6 month follow-up. The results will help inform scalable communication strategies to improve HPV vaccination uptake in low- and middle-income settings.
Eligibility Criteria
Inclusion Criteria: * Parent or primary caregiver of at least one girl aged 9-14 years * Parent states "no" or "unsure" to question asking if eligible daughter has received any doses of the HPV vaccine * Provides informed consent to participate Exclusion Criteria: * Parent or caregiver of a girl who has already received one or more doses of the HPV vaccine * Does not meet age eligibility criteria for an eligible daughter * Fails Attention Checks
Frequently Asked Questions
Who can join the NCT07498075 clinical trial?
This trial is open to participants of all sexes, aged 27 Years or older, studying HPV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07498075 currently recruiting?
Yes, NCT07498075 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Pennsylvania to inquire about joining.
Where is the NCT07498075 trial being conducted?
This trial is being conducted at Lagos, Nigeria.
Who is sponsoring the NCT07498075 clinical trial?
NCT07498075 is sponsored by University of Pennsylvania. The trial plans to enroll 3,340 participants.